Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc. (NASDAQ:NVAX ) was last seen up 1.6% at $74.25, after Israel inked a deal with the biotechnology concern to buy 5 million of its Covid-19 vaccine doses.

Novavax Inks Lofty Covid-19 Vaccine Deal with Israel

Novavax said it's on track to make 200 million doses per month by March. In early January, the Serum Institute had already made 200 million Novavax doses. A consortium says over 18 billion high-quality vaccine doses are likely needed in 2022. Novavax says, excluding China and Russia and children under 12, about 11.6 billion doses are needed.

Novavax Marches Ahead With Several Positive, Major Developments

Novavax Inc. NVAX, -7.91% said Friday it will supply 5 million doses of its protein-based COVID-19 vaccine to Israel as part of an advance purchase agreement, with the Israeli Ministry of Health also taking an option to buy an additional 5 million doses. "Novavax will work with the Ministry of Health to obtain the necessary authorizations and finalize plans for distribution in Israel pending regulatory approval," the company said in a statement.

Novavax to supply 5 million doses of its protein-based COVID vaccine to Israel in advance purchase agreement

GAITHERSBURG, Md. , Jan. 28, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Israel's Ministry of Health today announced an agreement for the purchase of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M™ adjuvant.

Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine

Investors appear to be concerned about Pfizer's and BioNTech's head start in developing an omicron-specific vaccine.

Why Novavax Stock Is Sinking Again This Week

From the shadows of missed deadlines, this company could become a common name in Covid vaccines

1 Top Biotech Stock Ready for a Bull Run

Teladoc

They both skyrocketed early in the pandemic.

Better Growth Stock: Novavax vs. Teladoc

Marathon Digital Holdings

Nikola

Vaxart

This diverse mix of companies is expected to deliver revenue growth of 236% to 5,460% this year.

4 of the Fastest-Growing Stocks on the Planet in 2022

BioNTech SE

Moderna

Pfizer

The CDC is making a push for fourth shots for the immuno-compromised.

Why Coronavirus Vaccine Stocks Topped the Market Today

An emergency use authorization in Australia is the latest example of the “yeah but” narrative that has plagued NVAX stock for the past year. The post Uncertain Market Conditions And Good News Make Novavax A Cautious Buy appeared first on InvestorPlace.

Uncertain Market Conditions And Good News Make Novavax A Cautious Buy

NVAX stock dropped precipitously of late, but investors with patience and a long view won't lose that patience as revenues start to roll in. The post Novavax Continues to Require Patience, But It Should Pay Off appeared first on InvestorPlace.

Novavax Continues to Require Patience, But It Should Pay Off

The stock has been impervious to rising after good news.

Down 57% in 1 Month, Is Novavax a Bargain Buy?

With time appearing to run out and fewer people willing to get vaccinated, NVAX stock seems to be an abandon-ship investment at this point. The post Novavax Appears to be Running Out of Options appeared first on InvestorPlace.

Novavax Appears to be Running Out of Options

Annaly Capital

This trio of discounted growth and value stocks is begging to be bought.

3 Top Stocks That Can Make You Richer in January (and Beyond)

The bullish case for owning COVID-19 vaccine makers is weakening as much of the world throws in the towel on trying to curb the spread of the coronavirus.

Why Vaccine Stocks Like Moderna and Novavax Tumbled (Again) Today

Novavax Inc. (NASDAQ:NVAX) shares lost ground Monday fell below support in a pennant pattern. The stock has also seen a strong drop in its Relative Strength Index.

Could Novavax Stock Be Due For A Reversal Soon?

Novavax could be losing ground in the vaccine war because it's fighting a battle on two fronts. This isn't helping NVAX stock move higher.

Novavax Is Fighting a Losing Battle on Two Fronts

Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels. The post Worldwide Adoption of Novavax Vaccines Makes It a Winner appeared first on InvestorPlace.

Worldwide Adoption of Novavax Vaccines Makes It a Winner

Twitter

They could be appealing options for contrarian investors.

2 Growth Stocks That Could Take Off in February

AbbVie

Valneva SE

Zogenix

Which biotech stocks are you watching today?

Top Biotech Stocks To Buy Now? 5 For Your Late January Watchlist

A new authorization from across the ocean fails to impress investors.

Why Novavax Stock Tumbled on Thursday

Once the vaccine maker starts booking big sales internationally, NVAX stock could make a trip back to much higher prices. The post Novavax Stock is in a Tough Spot, but its Fortunes Could Improve appeared first on InvestorPlace.

Novavax Stock is in a Tough Spot, but its Fortunes Could Improve

Ocugen, Inc.

Several factors are dragging down these vaccine stocks.

Why BioNTech, Moderna, Novavax, and Ocugen Stocks Are Plunging This Week

NVAX stock seems oversold. Focus on low-income countries is likely to deliver revenue and cash flows from covid-19 vaccine sales in 2022.

Novavax Is Oversold, Time To Buy for Future Growth

Novavax, Inc. (NASDAQ:NVAX) shares are trading higher Thursday after Australia's national drug regulator granted approval for the company's COVID-19 vaccine. The stock is trading below what traders call a pennant pattern and is showing uncertainty in where it could head next.

News for Novavax Stock (NVAX)